Newell, Kelly A. A/Prof

Selected Publications

• Journal Article

  Year	Title
  2020	The Wistar-Kyoto rat model of endogenous depression: A tool for exploring treatment resistance with an urgent need to focus on sex differences Published In Progress in Neuro-Psychopharmacology and Biological Psychiatry
  2019	Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders Published In Brain, Behavior, and Immunity
  2019	Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia Published In Progress in Neuro-Psychopharmacology and Biological Psychiatry
  2019	Increased translocator protein (TSPO) binding throughout neurodevelopment in the perinatal phencyclidine rodent model of schizophrenia Published In Schizophrenia Research
  2019	Perinatal exposure to fluoxetine increases anxiety- and depressive-like behaviours and alters glutamatergic markers in the prefrontal cortex and hippocampus of male adolescent rats: A comparison between Sprague-Dawley rats and the Wistar-Kyoto rat model of depression Published In Journal of Psychopharmacology
  2019	Tacrine-Hydrogen Sulfide Donor Hybrid Ameliorates Cognitive Impairment in the Aluminum Chloride Mouse Model of Alzheimer's Disease Published In ACS Chemical Neuroscience
  2018	A postmortem analysis of NMDA ionotropic and group 1 metabotropic glutamate receptors in the nucleus accumbens in schizophrenia Published In Journal of Psychiatry and Neuroscience
  2018	Chronic Adolescent CDPPB Treatment Alters Short-Term, but not Long-Term, Glutamatergic Receptor Expression Published In Neurochemical Research
  2018	Could an allied health care approach reduce the unacceptable incidence of suicide after psychiatric hospital discharge? Published In Bipolar Disorders: an international journal of psychiatry and neurosciences
  2018	Effects of common GRM5 genetic variants on cognition, hippocampal volume and mGluR5 protein levels in schizophrenia Published In Brain Imaging and Behavior: an international journal
  2018	Effects of short- and long-term aripiprazole treatment on Group I mGluRs in the nucleus accumbens: Comparison with haloperidol Published In Psychiatry Research
  2018	Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice Published In Journal of Neuroinflammation
  2018	Perinatal administration of phencyclidine alters expression of Lingo-1 signaling pathway proteins in the prefrontal cortex of juvenile and adult rats Published In Neuronal Signaling
  2017	Alterations of ubiquitin related proteins in the pathology and development of schizophrenia: Evidence from human and animal studies Published In Journal of Psychiatric Research
  2017	Dietary teasaponin ameliorates alteration of gut microbiota and cognitive decline in diet-induced obese mice Published In Scientific Reports
  2017	Effects of GRASP variation on memory in psychiatrically healthy individuals and cognitive dysfunction in schizophrenics Published In Gene Reports
  2017	Luteolin, a natural flavonoid, inhibits methylglyoxal induced apoptosis via the mTOR/4E-BP1 signaling pathway Published In Scientific Reports
  2017	Shifting towards a model of mGluR5 dysregulation in schizophrenia: consequences for future schizophrenia treatment Published In Neuropharmacology
  2017	The effects of maternal antidepressant use on offspring behaviour and brain development: Implications for risk of neurodevelopmental disorders Published In Neuroscience and Biobehavioral Reviews
  2016	Molecular evidence of synaptic pathology in CA1 in schizophrenia Published In Biological Psychiatry
  2016	Molecular evidence of synaptic pathology in the CA1 region in schizophrenia Published In NPJ Schizophrenia
  2016	Neurodevelopmental expression profile of dimeric and monomeric group 1 mGluRs: relevance to schizophrenia pathogenesis and treatment Published In Scientific Reports
  2016	Possibility of a sex-specific role for a genetic variant in FRMPD4 in schizophrenia, but not cognitive function Published In NeuroReport
  2016	The Neurodevelopmental Profile of Group 1 Metabotropic Glutamate Receptors: Implications for Novel Therapeutics Published In International Journal of Neuropsychopharmacology
  2016	mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia Published In Psychopharmacology
  2015	Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation Published In Acta Neuropathologica
  2015	Alterations of p75 neurotrophin receptor and Myelin transcription factor 1 in the hippocampus of perinatal phencyclidine treated rats Published In Progress in Neuro-Psychopharmacology and Biological Psychiatry
  2015	Genetic Variation in GRM5 is Associated with Cognition, Hippocampal Volume and Schizophrenia Published In Neuropsychopharmacology
  2015	Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia Published In Schizophrenia Research
  2015	NMDA receptor antagonism by phencyclidine reduces NWASP and WAVE1 protein expression and reduces levels of myelination markers in the prefrontal cortex of rats Published In Journal of Pharmaceutics & Pharmacology
  2014	GluN2B protein deficits in the left, but not the right, hippocampus in schizophrenia Published In BMC Psychiatry
  2014	Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics Published In Journal of Psychiatry and Neuroscience
  2014	Negativity towards negative results: a discussion of the disconnect between scientific worth and scientific culture Published In Disease Models and Mechanisms
  2014	Novel implications of Lingo-1 and its signaling partners in schizophrenia Published In Translational Psychiatry
  2014	Novel implications of lingo-1 signaling in the post-mortem schizophrenia brain Published In Biological Psychiatry
  2014	Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics Published In BMC Psychiatry
  2013	A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice Published In Neuroscience
  2013	Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment Published In Schizophrenia Research
  2013	Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs Published In Future Medicinal Chemistry
  2013	Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia Published In Neuroscience and Biobehavioral Reviews
  2013	Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia Published In Molecular Psychiatry
  2012	Perinatal phencyclidine treatment alters neuregulin 1/erbB4 expression and activation in later life Published In European Neuropsychopharmacology
  2011	Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age Published In Schizophrenia Research
  2011	Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin 1 and their role in schizophrenia Published In Progress in Neuro-Psychopharmacology and Biological Psychiatry
  2010	No change in 3H-Ifenprodil binding sites for the NR2B subunit in the prefrontal cortex in schizophrenia Published In Australian and New Zealand Journal of Psychiatry
  2010	Perinatal phencyclidine (PCP) treatment in schizophrenia research: of mice and rats Published In Australian and New Zealand Journal of Psychiatry
  2009	Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade Published In European Neuropsychopharmacology
  2009	High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: the association with the up-regulation of NMDA receptor binding in the rat brain Published In Experimental Neurology
  2009	Perinatal PCP treatment alters the developmental expression of prefrontal and hippocampal muscarinic receptors Published In Progress in Neuro-Psychopharmacology and Biological Psychiatry
  2009	The effects of developmental NMDA receptor antagonism on glutamate and acetylcholine receptor systems: a preliminary investigation of a two-hit animal model for Schizophrenia Published In Biological Psychiatry
  2008	Chronic treatment with simvastatin upregulates muscarinic M1/4 receptor binding in the rat brain Published In Neuroscience
  2008	Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain Published In Journal of Neuroscience Research
  2008	Perinatal NMDA receptor blockade alters D2, NMDA and M1/M4 receptors in later life: implications for pathological processes of schizophrenia Published In Schizophrenia Research
  2008	Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: implications for schizophrenia. Published In Journal of Chemical Neuroanatomy
  2008	Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression Published In Psychoneuroendocrinology
  2007	A rodent model of NMDA receptor hypofunction for the study of schizophrenia Published In Neuroscience Bulletin
  2007	Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia Published In Progress in Neuro-Psychopharmacology and Biological Psychiatry
  2007	Histamine H1 mRNA expression is decreased in the rat hypothalamus following olanzapine treatment Published In Schizophrenia Bulletin
  2007	NMDA receptor hypofunction during early brain development: relevance to schizophrenia Published In Schizophrenia Bulletin
  2007	No changes in cannabinoid CB1 receptor binding density in the superior temporal gyrus in schizophrenia Published In Schizophrenia Bulletin
  2007	Opposing short- and long-term effects on muscarinic M1/4 receptor binding following chronic phencyclidine treatment Published In Journal of Neuroscience Research
  2007	Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment Published In Journal of Neural Transmission
  2007	The posterior cingulate cortex: a site of altered neural circuitry in schizophrenia and NMDA hypofunction Published In Schizophrenia Bulletin

• Chapter

  Year	Title
  2014	Metabotropic glutamate receptor in the pathophysiology and treatment of schizophrenia and major depression Published In Metabotropic Glutamate Receptors: Molecular Mechanisms, Role in Neurological Disorders and Pharmacological Effects Publisher Now York

• Conference Paper

  Year	Title
  2015	Association of a genetic variant in FRMPD4, encoding for the multi-scaffolding protein Preso1, with schizophrenia and cognition Published In Australian Society for Medical Research NSW Scientific Meeting
  2015	Association of novel genetic variants in GRM5 with schizophrenia, cognition and hippocampal volume Published In Biological Psychiatry Australia Meeting
  2014	Alterations of mGluR5 and mGluR5 signaling partners in schizophrenia Published In Abstracts for 2014 Society for Neuroscience Annual Meeting
  2014	Effects of pharmacological blockade of Lingo - 1 signaling pathways in a phencyclidine rat model for schizophrenia Published In Abstracts for 2014 Society for Neuroscience Annual Meeting
  2014	Evidence of mGluR5 dysregulation in schizophrenia Published In Australian Neuroscience Society 34th Annual Meeting
  2014	Novel implications of Lingo-1 signaling in the prefrontal cortex and hippocampus of perinatal phencyclidine treated rats in a neurodevelopmental model of schizophrenia Published In Presentation Abstract of the Society of Biological Psychiatry 69th Annual Scientific Meeting
  2014	Novel implications of Lingo-1 signaling in the prefrontal cortex of perinatal phencyclidine treated rats in a neurodevelopmental model of schizophrenia Published In Abstract of 9th FENS Forum of Neuroscience
  2013	An analysis of metabotropic glutamate receptors 2/3 and 5 in schizophrenia, major depression and bipolar disorder from the stanley neuropathology consortium Published In 33rd Meeting of the Australian Neuroscience Society: Program, Abstracts & List of Registrants
  2013	Expression of proteins within the nogo receptor complex are altered in the dorsolateral prefrontal cortex in schizophrenia Published In 33rd Meeting of the Australian Neuroscience Society: Program, Abstracts & List of Registrants
  2013	Novel implications of Lingo-1 and its signalling partners in the Dorsolateral prefrontal cortex in schizophrenia Published In The 3rd Annual Biological Psychiatry Australia Scientific Meeting
  2013	Subchronic metabotropic glutamate 5 receptor modulation in the perinatal pcp rodent model of schizophrenia Published In 33rd Meeting of the Australian Neuroscience Society: Program, Abstracts & List of Registrants
  2012	Diagnostic-specific reductions in NMDA and mGlu5 glutamatergic receptors in schizophrenia Published In Australian Neuroscience Society 32nd Annual meeting
  2012	MGluR5 and NMDA receptor density are reduced in the dorsolateral prefrontal cortex of schizoaffective but not schizophrenia patients Published In Society of Biological Psychiatry 67th Annual Meeting
  2012	Metabotropic glutamate receptor subtype 5 is reduced in schizophrenia subjects with comorbid major depression and unchanged following antipsychotic drug treatment Published In Australian Neuroscience Society 32nd Annual meeting
  2012	Proteogenomic analyses of Lingo-1 and the Nogo receptor in schizophrenia Published In The 32nd Meeting of the Australian Neuroscience Society: Program, Abstracts & List of Registrants
  2012	The effects of phencyclidine treatment on the nmdar-nrg1 signalling pathway in rats Published In Australian Neuroscience Society 32nd Annual meeting
  2012	mGluR5 expression in the DLPFC of schizophrenia Published In Neuroscience Colloquium
  2011	Perinatal NR2B antagonism: effects on the developmental profile of NMDA receptor binding and NR2B binding in the mouse brain Published In 31st Annual Meeting of the Australian Neuroscience Society
  2011	The effect of phencyclidine treatment on neuregulin1 and ERBB4 receptor MRNA expression in the adult rat Published In 31st Annual Meeting of the Australian Neuroscience Society
  2010	Long term reductions in glutamatergic NMDA and dopaminergic D1 and D2 receptors in the rat brain following adolescent, but not perinatal, MK-801 treatment Published In ANS/AuPS 2010: Australian Neuroscience Society/Australian Physiological Society Joint Meeting
  2010	NMDA receptor and neuregulin1 signalling in the perinatal phencyclidine (PCP) animal model of schizophrenia Published In 7th FENS Forum of European Neuroscience, 2010 Amsterdam
  2010	Neuregulin1 and ERBB4 protein expression in the rat brain following perinatal phencyclidine treatment Published In ANS/AuPS 2010: Australian Neuroscience Society/Australian Physiological Society Joint Meeting
  2010	Neuregulin1 and ErbB4 protein levels are altered in the rat brain following perinatal NMDA receptor antagonism: implications for schizophrenia Published In 7th FENS Forum of European Neuroscience, 2010 Amsterdam
  2010	The effect of perinatal and adolescent brain development disruption from NMDA receptor antagonism on CB1 receptor levels in the rat prefrontal cortex Published In Australian Neuroscience Society/Australian Physiological Society
  2010	The effects of phencyclidine on the NMDAR/Neuregulin1 signalling complex: implications for schizophrenia Published In Australian Neuroscience Society/Australian Physiological Society
  2008	A mouse model for the schizophrenia candidate gene Neuregulin 1 - mechanisms behind an age-dependent and D9-tetrahydrocannabinol-sensitive behavioural phenotype Published In 18th Annual Symposium of the International Cannabinoid Research Society
  2007	Long-term consequences of early brain development disruption on neurochemical balance and behaviour Published In 7th IBRO World Congress of Neuroscience
  2007	Region-specific CB1 receptor changes in the rodent brain following NMDA receptor antagonism Published In 7th IBRO World Congress of Neurosciences

Investigator On

Year	Title
2021	Barnes Mazes for rats and mice Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2019	Rat activity wheel and living chamber system Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2018	Forced exercise/walking wheel system for rats Model 80805A Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2015	Defining the role of mGluR5 in the pathophysiology and treatment of schizophrenia Awarded by: Schizophrenia Fellowship of NSW Funding Scheme: Peter Meyer Fund
2014	SR-LAB ABS System Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2013 - 2014	Investigation of anti-Lingo-1 as an emergent actor in the therapy for schizophrenia Awarded by: Schizophrenia Research Institute Funding Scheme: Grant in Aid
2010	Precellys 24 tissue homogenizer and digital microplate shaker Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2009	NMDA receptor/neuregulin 1 signalling in response to phencyclidine administration Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Project Grant

Impact Story

Advisees

• Graduate Advising Relationship

  Degree	Research Title	Advisee
  Doctor of Philosophy	Characterisation of Alterations in Lipid Pathways in Huntington's Disease. A High-throughput Lipidomic Assessment of Disease Pathways .
  Doctor of Philosophy (Integrated)	Glutamatergic and Neurotrophic Signalling in the Pathology and Treatment of Psychiatric Illness.	Jarbou, Noor
  Doctor of Philosophy	Efficacy Investigation of Terpenes and Cannabidiol in a Rodent Model of Depression	Clunas, Helen
  Master of Philosophy -SMAH		Russell, Brooke
  Doctor of Philosophy	An Investigation of the Kynurenine Pathway in Major Depression	Brown, Samara

Keywords

• Animal model
• Antidepressant
• Brain development
• Depression
• Glutamate neurotransmission
• Maternal mental health
• Mental health
• Neurobiology
• Neuropharmacology
• Perinatal
• Postmortem human brain
• Pregnancy
• Psychopharmacology
• Schizophrenia

Orcid Id

• http://orcid.org/0000-0002-1245-5585 (confirmed)

Web Of Science Researcher Id

• K-5550-2014

Top Publications

Year	Title
2016	Neurodevelopmental expression profile of dimeric and monomeric group 1 mGluRs: relevance to schizophrenia pathogenesis and treatment Published in   Scientific Reports
2017	The effects of maternal antidepressant use on offspring behaviour and brain development: Implications for risk of neurodevelopmental disorders Published in   Neuroscience and Biobehavioral Reviews
2019	Perinatal exposure to fluoxetine increases anxiety- and depressive-like behaviours and alters glutamatergic markers in the prefrontal cortex and hippocampus of male adolescent rats: A comparison between Sprague-Dawley rats and the Wistar-Kyoto rat model of depression Published in   Journal of Psychopharmacology

Research Areas

• 1109 - NEUROSCIENCES
• Perinatal pharmacology (LCSH)
• Pharmacology (LCSH)
• Psychiatry (LCSH)
• Psychopharmacology (LCSH)

Research Overview

• My research priorities are in molecular psychiatry and neuro-psychopharmacology

  1. I use post-mortem human brain samples to investigate molecular changes that occur in psychiatric disorders, including schizophrenia and depression. I have a particular interest in the glutamatergic neurotransmission system in psychiatric disorders.

  2. I use animal models to investigate molecular changes that occur in the brain throughout normal brain development and how these neurodevelopmental molecular profiles change in animal models of  depression. I have a particular interest in the neurobiology of depression in special populations including pregnancy/postnatal and ageing and understanding the molecular mechanisms of treatments in these populations (including the impact of fetal exposure).

  3. I investigate the effects of current and novel antipsychotic and antidepressant drugs on brain molecules with a particular interest in how exposure to these drugs during the neonatal and adolescent periods, affects continued development of the brain and risk of developing subsequent psychiatric disorders.

  Brief Biography

  • Jan 2018 - : Associate Professor, School of Medicine, UoW
  • Jan 2012 - Dec 2017: Senior Lecturer, School of Medicine, UoW.
  • Dec 2007 – Dec 2011: Lecturer in Neuroscience, School of Health Sciences, UoW
  • 2007: PhD in Neuroscience (supervised by Prof Xu-Feng Huang and Dr Katerina Zavitsanou), School of Health Sciences, UoW.
  • 2006-2007: Short-term teaching contracts, School of Health Sciences, UoW.
  • 2002: Bachelor of Science (Biomedical Science) Honours, School of Health Sciences, UoW. 

Selected Publications

• Journal Article

  Year	Title
  2020	The Wistar-Kyoto rat model of endogenous depression: A tool for exploring treatment resistance with an urgent need to focus on sex differences Published In Progress in Neuro-Psychopharmacology and Biological Psychiatry
  2019	Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders Published In Brain, Behavior, and Immunity
  2019	Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia Published In Progress in Neuro-Psychopharmacology and Biological Psychiatry
  2019	Increased translocator protein (TSPO) binding throughout neurodevelopment in the perinatal phencyclidine rodent model of schizophrenia Published In Schizophrenia Research
  2019	Perinatal exposure to fluoxetine increases anxiety- and depressive-like behaviours and alters glutamatergic markers in the prefrontal cortex and hippocampus of male adolescent rats: A comparison between Sprague-Dawley rats and the Wistar-Kyoto rat model of depression Published In Journal of Psychopharmacology
  2019	Tacrine-Hydrogen Sulfide Donor Hybrid Ameliorates Cognitive Impairment in the Aluminum Chloride Mouse Model of Alzheimer's Disease Published In ACS Chemical Neuroscience
  2018	A postmortem analysis of NMDA ionotropic and group 1 metabotropic glutamate receptors in the nucleus accumbens in schizophrenia Published In Journal of Psychiatry and Neuroscience
  2018	Chronic Adolescent CDPPB Treatment Alters Short-Term, but not Long-Term, Glutamatergic Receptor Expression Published In Neurochemical Research
  2018	Could an allied health care approach reduce the unacceptable incidence of suicide after psychiatric hospital discharge? Published In Bipolar Disorders: an international journal of psychiatry and neurosciences
  2018	Effects of common GRM5 genetic variants on cognition, hippocampal volume and mGluR5 protein levels in schizophrenia Published In Brain Imaging and Behavior: an international journal
  2018	Effects of short- and long-term aripiprazole treatment on Group I mGluRs in the nucleus accumbens: Comparison with haloperidol Published In Psychiatry Research
  2018	Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice Published In Journal of Neuroinflammation
  2018	Perinatal administration of phencyclidine alters expression of Lingo-1 signaling pathway proteins in the prefrontal cortex of juvenile and adult rats Published In Neuronal Signaling
  2017	Alterations of ubiquitin related proteins in the pathology and development of schizophrenia: Evidence from human and animal studies Published In Journal of Psychiatric Research
  2017	Dietary teasaponin ameliorates alteration of gut microbiota and cognitive decline in diet-induced obese mice Published In Scientific Reports
  2017	Effects of GRASP variation on memory in psychiatrically healthy individuals and cognitive dysfunction in schizophrenics Published In Gene Reports
  2017	Luteolin, a natural flavonoid, inhibits methylglyoxal induced apoptosis via the mTOR/4E-BP1 signaling pathway Published In Scientific Reports
  2017	Shifting towards a model of mGluR5 dysregulation in schizophrenia: consequences for future schizophrenia treatment Published In Neuropharmacology
  2017	The effects of maternal antidepressant use on offspring behaviour and brain development: Implications for risk of neurodevelopmental disorders Published In Neuroscience and Biobehavioral Reviews
  2016	Molecular evidence of synaptic pathology in CA1 in schizophrenia Published In Biological Psychiatry
  2016	Molecular evidence of synaptic pathology in the CA1 region in schizophrenia Published In NPJ Schizophrenia
  2016	Neurodevelopmental expression profile of dimeric and monomeric group 1 mGluRs: relevance to schizophrenia pathogenesis and treatment Published In Scientific Reports
  2016	Possibility of a sex-specific role for a genetic variant in FRMPD4 in schizophrenia, but not cognitive function Published In NeuroReport
  2016	The Neurodevelopmental Profile of Group 1 Metabotropic Glutamate Receptors: Implications for Novel Therapeutics Published In International Journal of Neuropsychopharmacology
  2016	mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia Published In Psychopharmacology
  2015	Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation Published In Acta Neuropathologica
  2015	Alterations of p75 neurotrophin receptor and Myelin transcription factor 1 in the hippocampus of perinatal phencyclidine treated rats Published In Progress in Neuro-Psychopharmacology and Biological Psychiatry
  2015	Genetic Variation in GRM5 is Associated with Cognition, Hippocampal Volume and Schizophrenia Published In Neuropsychopharmacology
  2015	Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia Published In Schizophrenia Research
  2015	NMDA receptor antagonism by phencyclidine reduces NWASP and WAVE1 protein expression and reduces levels of myelination markers in the prefrontal cortex of rats Published In Journal of Pharmaceutics & Pharmacology
  2014	GluN2B protein deficits in the left, but not the right, hippocampus in schizophrenia Published In BMC Psychiatry
  2014	Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics Published In Journal of Psychiatry and Neuroscience
  2014	Negativity towards negative results: a discussion of the disconnect between scientific worth and scientific culture Published In Disease Models and Mechanisms
  2014	Novel implications of Lingo-1 and its signaling partners in schizophrenia Published In Translational Psychiatry
  2014	Novel implications of lingo-1 signaling in the post-mortem schizophrenia brain Published In Biological Psychiatry
  2014	Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics Published In BMC Psychiatry
  2013	A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice Published In Neuroscience
  2013	Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment Published In Schizophrenia Research
  2013	Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs Published In Future Medicinal Chemistry
  2013	Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia Published In Neuroscience and Biobehavioral Reviews
  2013	Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia Published In Molecular Psychiatry
  2012	Perinatal phencyclidine treatment alters neuregulin 1/erbB4 expression and activation in later life Published In European Neuropsychopharmacology
  2011	Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age Published In Schizophrenia Research
  2011	Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin 1 and their role in schizophrenia Published In Progress in Neuro-Psychopharmacology and Biological Psychiatry
  2010	No change in 3H-Ifenprodil binding sites for the NR2B subunit in the prefrontal cortex in schizophrenia Published In Australian and New Zealand Journal of Psychiatry
  2010	Perinatal phencyclidine (PCP) treatment in schizophrenia research: of mice and rats Published In Australian and New Zealand Journal of Psychiatry
  2009	Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade Published In European Neuropsychopharmacology
  2009	High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: the association with the up-regulation of NMDA receptor binding in the rat brain Published In Experimental Neurology
  2009	Perinatal PCP treatment alters the developmental expression of prefrontal and hippocampal muscarinic receptors Published In Progress in Neuro-Psychopharmacology and Biological Psychiatry
  2009	The effects of developmental NMDA receptor antagonism on glutamate and acetylcholine receptor systems: a preliminary investigation of a two-hit animal model for Schizophrenia Published In Biological Psychiatry
  2008	Chronic treatment with simvastatin upregulates muscarinic M1/4 receptor binding in the rat brain Published In Neuroscience
  2008	Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain Published In Journal of Neuroscience Research
  2008	Perinatal NMDA receptor blockade alters D2, NMDA and M1/M4 receptors in later life: implications for pathological processes of schizophrenia Published In Schizophrenia Research
  2008	Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: implications for schizophrenia. Published In Journal of Chemical Neuroanatomy
  2008	Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression Published In Psychoneuroendocrinology
  2007	A rodent model of NMDA receptor hypofunction for the study of schizophrenia Published In Neuroscience Bulletin
  2007	Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia Published In Progress in Neuro-Psychopharmacology and Biological Psychiatry
  2007	Histamine H1 mRNA expression is decreased in the rat hypothalamus following olanzapine treatment Published In Schizophrenia Bulletin
  2007	NMDA receptor hypofunction during early brain development: relevance to schizophrenia Published In Schizophrenia Bulletin
  2007	No changes in cannabinoid CB1 receptor binding density in the superior temporal gyrus in schizophrenia Published In Schizophrenia Bulletin
  2007	Opposing short- and long-term effects on muscarinic M1/4 receptor binding following chronic phencyclidine treatment Published In Journal of Neuroscience Research
  2007	Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment Published In Journal of Neural Transmission
  2007	The posterior cingulate cortex: a site of altered neural circuitry in schizophrenia and NMDA hypofunction Published In Schizophrenia Bulletin

• Chapter

  Year	Title
  2014	Metabotropic glutamate receptor in the pathophysiology and treatment of schizophrenia and major depression Published In Metabotropic Glutamate Receptors: Molecular Mechanisms, Role in Neurological Disorders and Pharmacological Effects Publisher Now York

• Conference Paper

  Year	Title
  2015	Association of a genetic variant in FRMPD4, encoding for the multi-scaffolding protein Preso1, with schizophrenia and cognition Published In Australian Society for Medical Research NSW Scientific Meeting
  2015	Association of novel genetic variants in GRM5 with schizophrenia, cognition and hippocampal volume Published In Biological Psychiatry Australia Meeting
  2014	Alterations of mGluR5 and mGluR5 signaling partners in schizophrenia Published In Abstracts for 2014 Society for Neuroscience Annual Meeting
  2014	Effects of pharmacological blockade of Lingo - 1 signaling pathways in a phencyclidine rat model for schizophrenia Published In Abstracts for 2014 Society for Neuroscience Annual Meeting
  2014	Evidence of mGluR5 dysregulation in schizophrenia Published In Australian Neuroscience Society 34th Annual Meeting
  2014	Novel implications of Lingo-1 signaling in the prefrontal cortex and hippocampus of perinatal phencyclidine treated rats in a neurodevelopmental model of schizophrenia Published In Presentation Abstract of the Society of Biological Psychiatry 69th Annual Scientific Meeting
  2014	Novel implications of Lingo-1 signaling in the prefrontal cortex of perinatal phencyclidine treated rats in a neurodevelopmental model of schizophrenia Published In Abstract of 9th FENS Forum of Neuroscience
  2013	An analysis of metabotropic glutamate receptors 2/3 and 5 in schizophrenia, major depression and bipolar disorder from the stanley neuropathology consortium Published In 33rd Meeting of the Australian Neuroscience Society: Program, Abstracts & List of Registrants
  2013	Expression of proteins within the nogo receptor complex are altered in the dorsolateral prefrontal cortex in schizophrenia Published In 33rd Meeting of the Australian Neuroscience Society: Program, Abstracts & List of Registrants
  2013	Novel implications of Lingo-1 and its signalling partners in the Dorsolateral prefrontal cortex in schizophrenia Published In The 3rd Annual Biological Psychiatry Australia Scientific Meeting
  2013	Subchronic metabotropic glutamate 5 receptor modulation in the perinatal pcp rodent model of schizophrenia Published In 33rd Meeting of the Australian Neuroscience Society: Program, Abstracts & List of Registrants
  2012	Diagnostic-specific reductions in NMDA and mGlu5 glutamatergic receptors in schizophrenia Published In Australian Neuroscience Society 32nd Annual meeting
  2012	MGluR5 and NMDA receptor density are reduced in the dorsolateral prefrontal cortex of schizoaffective but not schizophrenia patients Published In Society of Biological Psychiatry 67th Annual Meeting
  2012	Metabotropic glutamate receptor subtype 5 is reduced in schizophrenia subjects with comorbid major depression and unchanged following antipsychotic drug treatment Published In Australian Neuroscience Society 32nd Annual meeting
  2012	Proteogenomic analyses of Lingo-1 and the Nogo receptor in schizophrenia Published In The 32nd Meeting of the Australian Neuroscience Society: Program, Abstracts & List of Registrants
  2012	The effects of phencyclidine treatment on the nmdar-nrg1 signalling pathway in rats Published In Australian Neuroscience Society 32nd Annual meeting
  2012	mGluR5 expression in the DLPFC of schizophrenia Published In Neuroscience Colloquium
  2011	Perinatal NR2B antagonism: effects on the developmental profile of NMDA receptor binding and NR2B binding in the mouse brain Published In 31st Annual Meeting of the Australian Neuroscience Society
  2011	The effect of phencyclidine treatment on neuregulin1 and ERBB4 receptor MRNA expression in the adult rat Published In 31st Annual Meeting of the Australian Neuroscience Society
  2010	Long term reductions in glutamatergic NMDA and dopaminergic D1 and D2 receptors in the rat brain following adolescent, but not perinatal, MK-801 treatment Published In ANS/AuPS 2010: Australian Neuroscience Society/Australian Physiological Society Joint Meeting
  2010	NMDA receptor and neuregulin1 signalling in the perinatal phencyclidine (PCP) animal model of schizophrenia Published In 7th FENS Forum of European Neuroscience, 2010 Amsterdam
  2010	Neuregulin1 and ERBB4 protein expression in the rat brain following perinatal phencyclidine treatment Published In ANS/AuPS 2010: Australian Neuroscience Society/Australian Physiological Society Joint Meeting
  2010	Neuregulin1 and ErbB4 protein levels are altered in the rat brain following perinatal NMDA receptor antagonism: implications for schizophrenia Published In 7th FENS Forum of European Neuroscience, 2010 Amsterdam
  2010	The effect of perinatal and adolescent brain development disruption from NMDA receptor antagonism on CB1 receptor levels in the rat prefrontal cortex Published In Australian Neuroscience Society/Australian Physiological Society
  2010	The effects of phencyclidine on the NMDAR/Neuregulin1 signalling complex: implications for schizophrenia Published In Australian Neuroscience Society/Australian Physiological Society
  2008	A mouse model for the schizophrenia candidate gene Neuregulin 1 - mechanisms behind an age-dependent and D9-tetrahydrocannabinol-sensitive behavioural phenotype Published In 18th Annual Symposium of the International Cannabinoid Research Society
  2007	Long-term consequences of early brain development disruption on neurochemical balance and behaviour Published In 7th IBRO World Congress of Neuroscience
  2007	Region-specific CB1 receptor changes in the rodent brain following NMDA receptor antagonism Published In 7th IBRO World Congress of Neurosciences

Investigator On

Year	Title
2021	Barnes Mazes for rats and mice Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2019	Rat activity wheel and living chamber system Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2018	Forced exercise/walking wheel system for rats Model 80805A Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2015	Defining the role of mGluR5 in the pathophysiology and treatment of schizophrenia Awarded by: Schizophrenia Fellowship of NSW Funding Scheme: Peter Meyer Fund
2014	SR-LAB ABS System Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2013 - 2014	Investigation of anti-Lingo-1 as an emergent actor in the therapy for schizophrenia Awarded by: Schizophrenia Research Institute Funding Scheme: Grant in Aid
2010	Precellys 24 tissue homogenizer and digital microplate shaker Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Equipment Grant
2009	NMDA receptor/neuregulin 1 signalling in response to phencyclidine administration Awarded by: National Health and Medical Research Council (NHMRC) Funding Scheme: Project Grant

Impact Story

Advisees

• Graduate Advising Relationship

  Degree	Research Title	Advisee
  Doctor of Philosophy	Characterisation of Alterations in Lipid Pathways in Huntington's Disease. A High-throughput Lipidomic Assessment of Disease Pathways .
  Doctor of Philosophy (Integrated)	Glutamatergic and Neurotrophic Signalling in the Pathology and Treatment of Psychiatric Illness.	Jarbou, Noor
  Doctor of Philosophy	Efficacy Investigation of Terpenes and Cannabidiol in a Rodent Model of Depression	Clunas, Helen
  Master of Philosophy -SMAH		Russell, Brooke
  Doctor of Philosophy	An Investigation of the Kynurenine Pathway in Major Depression	Brown, Samara

Keywords

• Animal model
• Antidepressant
• Brain development
• Depression
• Glutamate neurotransmission
• Maternal mental health
• Mental health
• Neurobiology
• Neuropharmacology
• Perinatal
• Postmortem human brain
• Pregnancy
• Psychopharmacology
• Schizophrenia

Orcid Id

• http://orcid.org/0000-0002-1245-5585 (confirmed)

Web Of Science Researcher Id

• K-5550-2014